JP7477457B2 - Ｃ３結合薬及びその使用方法 - Google Patents

Ｃ３結合薬及びその使用方法 Download PDF

Info

Publication number
JP7477457B2
JP7477457B2 JP2020554097A JP2020554097A JP7477457B2 JP 7477457 B2 JP7477457 B2 JP 7477457B2 JP 2020554097 A JP2020554097 A JP 2020554097A JP 2020554097 A JP2020554097 A JP 2020554097A JP 7477457 B2 JP7477457 B2 JP 7477457B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554097A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520195A5 (https=
JP2021520195A (ja
JPWO2019195136A5 (https=
Inventor
ダナ イェン メイ デューイ，
ジョンハオ リウ，
ジエ タン，
ヤン ワン，
イユアン イン，
ウェンウー ジャイ，
ジャレッド マーティン ヒグビー，
Original Assignee
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エヌジーエム バイオファーマシューティカルス，インコーポレーテッド filed Critical エヌジーエム バイオファーマシューティカルス，インコーポレーテッド
Publication of JP2021520195A publication Critical patent/JP2021520195A/ja
Publication of JP2021520195A5 publication Critical patent/JP2021520195A5/ja
Publication of JPWO2019195136A5 publication Critical patent/JPWO2019195136A5/ja
Priority to JP2024019502A priority Critical patent/JP2024056851A/ja
Application granted granted Critical
Publication of JP7477457B2 publication Critical patent/JP7477457B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020554097A 2018-04-03 2019-04-01 Ｃ３結合薬及びその使用方法 Active JP7477457B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024019502A JP2024056851A (ja) 2018-04-03 2024-02-13 Ｃ３結合薬及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862652253P 2018-04-03 2018-04-03
US62/652,253 2018-04-03
PCT/US2019/025123 WO2019195136A1 (en) 2018-04-03 2019-04-01 C3-binding agents and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019502A Division JP2024056851A (ja) 2018-04-03 2024-02-13 Ｃ３結合薬及びその使用方法

Publications (4)

Publication Number Publication Date
JP2021520195A JP2021520195A (ja) 2021-08-19
JP2021520195A5 JP2021520195A5 (https=) 2022-04-08
JPWO2019195136A5 JPWO2019195136A5 (https=) 2022-04-08
JP7477457B2 true JP7477457B2 (ja) 2024-05-01

Family

ID=66630340

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020554097A Active JP7477457B2 (ja) 2018-04-03 2019-04-01 Ｃ３結合薬及びその使用方法
JP2024019502A Pending JP2024056851A (ja) 2018-04-03 2024-02-13 Ｃ３結合薬及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024019502A Pending JP2024056851A (ja) 2018-04-03 2024-02-13 Ｃ３結合薬及びその使用方法

Country Status (18)

Country Link
US (3) US11136381B2 (https=)
EP (1) EP3790897A1 (https=)
JP (2) JP7477457B2 (https=)
KR (1) KR20200138290A (https=)
CN (1) CN112105638A (https=)
AR (1) AR117565A1 (https=)
AU (1) AU2019248557A1 (https=)
BR (1) BR112020019907A2 (https=)
CA (1) CA3093356A1 (https=)
CL (2) CL2020002522A1 (https=)
CO (1) CO2020013468A2 (https=)
IL (1) IL277404A (https=)
MX (1) MX2020010323A (https=)
PE (1) PE20212132A1 (https=)
PH (1) PH12020500664A1 (https=)
SG (1) SG11202008897SA (https=)
TW (1) TWI833742B (https=)
WO (1) WO2019195136A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof
WO2021226442A2 (en) * 2020-05-08 2021-11-11 Ngm Biopharmaceuticals, Inc. Therapeutic uses of c3-binding agents
US20230381269A1 (en) * 2020-09-21 2023-11-30 Apellis Pharmaceuticals, Inc. Methods of treating eye disorders
CN116848136A (zh) * 2021-02-12 2023-10-03 勃林格殷格翰国际有限公司 补体c3抗原结合蛋白
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
WO2024086555A1 (en) 2022-10-17 2024-04-25 Ngm Biopharmaceuticals, Inc. Uses of anti-c3 antibodies
CN117447601B (zh) * 2023-12-22 2024-03-08 北京索莱宝科技有限公司 猪IgM的抗体、抗体组合物及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031240A1 (en) 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
JP2012525829A (ja) 2009-05-06 2012-10-25 ノバルティス アーゲー 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法
JP2015514112A (ja) 2012-04-03 2015-05-18 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01002580A (es) * 1998-09-10 2002-04-08 Univ Virginia Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas.
US7816497B2 (en) 2002-10-30 2010-10-19 University Of Kentucky Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
WO2004041867A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against imminoglobulin e and use thereof for the treatment of allergic disorders
US20090004183A1 (en) 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
WO2006083533A2 (en) 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
EP3299027A1 (en) 2005-11-04 2018-03-28 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8192742B2 (en) 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
BRPI0812767A2 (pt) 2007-06-07 2014-12-02 Genentech Inc Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento
RU2548807C2 (ru) 2009-05-20 2015-04-20 Торэй Индастриз, Инк. Пептиды, проникающие в клетку
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20130177567A1 (en) 2010-05-18 2013-07-11 Sydansk Universitet Novel c3c epitope, antibodies binding thereto, and use thereof
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
WO2015099838A2 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
AU2015360502A1 (en) * 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
US20180346531A1 (en) 2015-09-15 2018-12-06 Regents Of The University Of California Compositions and methods for delivering biotherapeutics
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
EP3654941A1 (en) 2017-07-17 2020-05-27 Keith Roizman Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases
WO2019195136A1 (en) 2018-04-03 2019-10-10 Ngm Biopharmaceuticals, Inc. C3-binding agents and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031240A1 (en) 2002-10-04 2004-04-15 Stichting Sanquin Bloedvoorziening Monoclonal antibody anti-c3-2 directed against the third component of complement (c3) and its use in methods to inhibit complement activation
JP2012525829A (ja) 2009-05-06 2012-10-25 ノバルティス アーゲー 補体タンパク質Ｃ３ｂを標的とする抗体の組成物および方法
JP2015514112A (ja) 2012-04-03 2015-05-18 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Journal of Immunology，2017年，Vol.47，pp.504-515

Also Published As

Publication number Publication date
EP3790897A1 (en) 2021-03-17
CN112105638A (zh) 2020-12-18
TW202003559A (zh) 2020-01-16
RU2020135712A (ru) 2022-05-04
JP2024056851A (ja) 2024-04-23
US20230382985A1 (en) 2023-11-30
JP2021520195A (ja) 2021-08-19
US20190322730A1 (en) 2019-10-24
KR20200138290A (ko) 2020-12-09
SG11202008897SA (en) 2020-10-29
WO2019195136A1 (en) 2019-10-10
US20220119508A1 (en) 2022-04-21
CL2020002522A1 (es) 2021-02-26
MX2020010323A (es) 2021-01-08
PE20212132A1 (es) 2021-11-05
CA3093356A1 (en) 2019-10-10
AR117565A1 (es) 2021-08-18
US11136381B2 (en) 2021-10-05
BR112020019907A2 (pt) 2021-01-05
TWI833742B (zh) 2024-03-01
IL277404A (en) 2020-11-30
AU2019248557A1 (en) 2020-09-24
CL2021002039A1 (es) 2022-04-01
US11767359B2 (en) 2023-09-26
CO2020013468A2 (es) 2020-11-10
PH12020500664A1 (en) 2021-06-07

Similar Documents

Publication Publication Date Title
JP7477457B2 (ja) Ｃ３結合薬及びその使用方法
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
US20150368329A1 (en) Methods of Treating Ocular Diseases
US11780916B2 (en) GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
CA3080148A1 (en) Angptl8-binding agents and methods of use thereof
US20220251241A1 (en) Htra1-binding agents and methods of use thereof
US11542336B2 (en) GCGR antibody and GLP-1 fusion protein thereof, pharmaceutical composition thereof and application thereof
WO2021226442A2 (en) Therapeutic uses of c3-binding agents
US20250270328A1 (en) Klrb1 binding agents and methods of use thereof
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
US12221488B2 (en) APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01
US10064937B2 (en) Treatment of dermal fibrosis
WO2023241389A1 (zh) 针对tfpi的单克隆抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240213

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240418

R150 Certificate of patent or registration of utility model

Ref document number: 7477457

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150